22 Jun EULAR 2024: Gout Remission Achieved with Intensive Urate-Lowering KRYSTEXXA (pegloticase)
MedicalResearch.com Interview with:
Dr. LaMoreaux
Brian LaMoreaux, MD, MS
Internist and Rheumatologist
Executive Medical Director, Amgen
MedicalResearch.com: What is the background for this study? How does KRYSTEXXA® (pegloticase) work in gout?
Response: Many other diseases in gout have well-defined definitions of remission, but gout has lagged behind on this. With systemic consequences of gout becoming more apparent, the concept of treating gout to remission is increasing important to improving patient care and preserving patient health.
Our MIRROR randomized controlled trial (RCT) provides data beyond the primary and secondary endpoints and allows us to look at aspects like the rate of gout remission (i.e. serum urate level (SU) <6 mg/dL, absence of acute gout flare, absence of tophi, minimal gout-related pain, and minimal gout-related quality-of-life impact over a 12-month period) achieved with KRYSTEXXA-induced intensive urate-lowering. Continuing to advance knowledge that can positively impact patient care is our driving force for the research.
KRYSTEXXA is approved for the treatment of uncontrolled gout, for those experiencing signs and symptoms of gout despite taking oral medicines. It is the only gout treatment that controls uncontrolled gout by changing uric acid into a water-soluble substance called allantoin that he body easily gets rid of through urine.
MedicalResearch.com: What are the main findings?
Response: Based on the MIRROR RCT data, nearly half (47%) treated with KRYSTEXXA for 52 weeks achieved remission. This gout remission analysis provides further evidence on the overall efficacy of KRYSTEXXA to effectively and expeditiously treat uncontrolled gout patients, but also that KRYSTEXXA treatment longer than 6 months may provide accrued clinical beneficial to patients.
In addition, these data show that successful intensive serum urate lowering with KRYSTEXXA and resulting urate depletion improve both gout signs/symptoms and patient quality-of-life.
MedicalResearch.com: What should readers take away from your report?
Response: The data provide insight on how sustained, intensive serum urate-lowering with KRYSTEXXA, and subsequent urate depletion, can result in a marked reduction of gout signs and symptoms and an improvement in patient quality of life.
MedicalResearch.com: What recommendations do you have for future research as a results of this study?
Response: Uncontrolled gout has historically been under-researched as a disease. We believe it is important to continue to work with the clinical community to identify elements that can help inform treatment approaches. This analysis shows remission in gout is possible with serum urate lowering, which improves disease understanding and potentially patient care.
MedicalResearch.com: Is there anything else you would like to add? Any disclosures?
Response: These data, when coupled with the findings on how gout remission is viewed by physicians who treat gout, highlight how widespread adoption of a gout remission definition could help standardize gout care for patients, particularly with respect to serum urate-lowering. We hope to generate and participate in more discussions on defining and achieving gout remission as furthering this topic will greatly improve patient care in gout.
Dr. Brian LaMoreaux reports employment with Amgen. Please see the study for all other authors’ relevant financial disclosures.
Citation: EULAR 2024 abstract June 2024
Klionsky Y, Torralba K, Obermeyer K, et al
POS0239 ACHIEVEMENT OF “GOUT REMISSION” DURING INTENSIVE URATE-LOWERING OVER 52 WEEKS OF PEGLOTICASE THERAPY
Annals of the Rheumatic Diseases 2024;83:405.
https://ard.bmj.com/content/83/Suppl_1/405.1.citation-tools
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition.
Some links may be sponsored. Products are not endorsed.
Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on June 22, 2024 by Marie Benz MD FAAD